European Perspective on 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: Proceedings of an Interactive International Symposium
Open accessThe DOI matches its Crossref record; 120 of the 120 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The American Thyroid Association (ATA) management guidelines for patients with thyroid nodules and differentiated thyroid cancer (DTC) are highly influential practice recommendations. The latest revision appeared in 2015 ("ATA 2015"). These guidelines were developed predominantly by North American experts. European experts frequently have different perspectives, given epidemiological, technological/methodological, practice organization, and medicolegal differences between the respective regions. SUMMARY: Divergent viewpoints were the focus of an invited symposium organized by the European Association of Nuclear Medicine involving 17 European thyroidologists, four ATA Guidelines Taskforce members, and an audience of 200 international experts. The group discussed the preoperative assessment of thyroid nodules, surgery and the role of pathology, radioiodine (RAI) therapy (RAIT), the assessment of initial therapy and dynamic risk stratification, and the treatment of persistent disease, recurrences, and advanced thyroid cancer. The dialogue resulted in this position paper contrasting European and ATA 2015 perspectives on key issues. One difference pertains to the permissiveness of ATA 2015 regarding lobectomy for primary tumors ≤4 cm. European panelists cited preclusion of RAIT, potential need for completion thyroidectomy, frequent inability to avoid chronic thyroid hormone replacement, and limitations of supportive evidence as arguments against widely applying lobectomy. Significant divergence involved ATA 2015's guidance regarding RAIT. European panelists favored wider use of postoperative RAIT than does ATA 2015. Rationales included the modality's association with favorable patient outcomes and generally limited toxicity, and lack of high-quality evidence supporting withholding RAIT. Additionally, European panelists favored recombinant human thyrotropin (rhTSH) in more settings than does ATA 2015, citing avoidance of hypothyroid morbidity and quality-of-life impairment, without apparent sacrifice in oncologic outcomes. Based on clinical evidence plus theoretical advantages, European experts advocated dosimetric versus fixed-activity RAIT approaches for advanced DTC. European panelists noted that the ATA 2015 risk-stratification system requires information sometimes unavailable in everyday practice. ATA 2015 recommendations regarding RAI-refractory DTC should consider potential palliative benefits of RAIT in patients who also have RAI-susceptible lesions. CONCLUSIONS: European panelists suggested modifications to approximately one-third of ATA 2015 recommendations. Varying European and ATA 2015 perspectives can stimulate analysis and discussion of the literature and performance of primary research to resolve discrepant recommendations and potentially improve patient outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Haugen, B. R., Alexander, E. K., Bible, K. C., Doherty, G. M., Mandel, S. J., Nikiforov, Y. E., Pacini, F., Randolph, G. W., Sawka, A. M., Schlumberger, M., et al. (2016) · Thyroid® · doi:10.1089/thy.2015.0020 · Cited by 16,535
Self-citationCooper, D. S., Doherty, G. M., Haugen, B. R., Kloos, R. T., Lee, S. L., Mandel, S. J., Mazzaferri, E. L., McIver, B., Pacini, F., Schlumberger, M., et al. (2009) · Thyroid · doi:10.1089/thy.2009.0110 · Cited by 6,707
Self-citationACR Thyroid Imaging, Reporting and Data System (TI-RADS): White Paper of the ACR TI-RADS Committee
Tessler, F. N., Middleton, W. D., Grant, E. G., Hoang, J. K., Berland, L. L., Teefey, S. A., Cronan, J. J., Beland, M. D., Desser, T. S., Frates, M. C., et al. (2017) · Journal of the American College of Radiology · doi:10.1016/j.jacr.2017.01.046 · Cited by 2,530 · cited 1×
“(28), including emerging and promising web-based versions.”
Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer
Schlumberger, M., Tahara, M., Wirth, L. J., Robinson, B., Brose, M. S., Elisei, R., Habra, M. A., Newbold, K., Shah, M. H., Hoff, A. O., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1406470 · Cited by 2,096 · cited 1×
“Although kinase inhibitors were approved in some countries based on Phase II trials (133), the benefits of these drugs have been established in RCTs (134,135).”
Self-citationPacini, F., Schlumberger, M., Dralle, H., Elisei, R., Smit, J. W. A., Wiersinga, W., & _, _. (2006) · European Journal of Endocrinology · doi:10.1530/eje.1.02158 · Cited by 1,976 · cited 1×
“…European panelists felt that a stronger endorsement of rhTSH preparation is warranted in most settings, as is found in the EANM guidelines for RAIT (87), European Society for Molecular Oncology thyroid cancer guidelines (88), or a European expert consensus statement (89) (Supplementary Table S3).”
Self-citationThe 2017 Bethesda System for Reporting Thyroid Cytopathology
Cibas, E. S., & Ali, S. Z. (2017) · Thyroid · doi:10.1089/thy.2017.0500 · Cited by 1,844 · cited 1×
“The recent update (29) of The Bethesda System for Reporting Thyroid Cytopathology is, in our opinion, an improvement over the previous version (30).”
Durante, C., Haddy, N., Baudin, E., Leboulleux, S., Hartl, D., Travagli, J. P., Caillou, B., Ricard, M., Lumbroso, J. D., De Vathaire, F., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2838 · Cited by 1,675
Brose, M. S., Nutting, C. M., Jarzab, B., Elisei, R., Siena, S., Bastholt, L., de la Fouchardiere, C., Pacini, F., Paschke, R., Shong, Y. K., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60421-9 · Cited by 1,663
Self-citationNikiforov, Y. E., Seethala, R. R., Tallini, G., Baloch, Z. W., Basolo, F., Thompson, L. D. R., Barletta, J. A., Wenig, B. M., Al Ghuzlan, A., Kakudo, K., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.0386 · Cited by 1,404 · cited 1×
“…with papillary-like nuclear fea-tures’’ classification and the finding of RAS mutations or PAX8-PPR c rearrangements, among others, in histolog-icallybenignnodules (39,40),together withthe increased emphasis on ultrasonography, may limit the role of molecular testing to ruling out malignancy (41).”
Self-citationRuss, G., Bonnema, S. J., Erdogan, M. F., Durante, C., Ngu, R., & Leenhardt, L. (2017) · European Thyroid Journal · doi:10.1159/000478927 · Cited by 1,284 · cited 3×
“Together with the simplicity of the system, these user-friendly features should promote inter-observer reproducibility of descriptions and facilitate the presentation of results (20).”
Self-citation
Cited by
Alexander, E. K., & Cibas, E. S. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00101-2 · Cited by 254
Seeking optimization of LT4 treatment in patients with differentiated thyroid cancer
Stramazzo, I., Capriello, S., Antonelli, A., Fallahi, P., Centanni, M., & Virili, C. (2022) · HORMONES · doi:10.1007/s42000-022-00376-9 · Cited by 9
“The choice is based on the major Society guidelines on differentiated thyroid cancer (DTC representing 90% of thyroid tumors) [2, 3], depending on tumor size, invasion, local or distant metastasis, and response to therapy (see below).”
Background
Metadata
- Authors
- Luster, M., Aktolun, C., Amendoeira, I., Barczyński, M., Bible, K. C., Duntas, L. H., Elisei, R., Handkiewicz-Junak, D., Hoffmann, M., Jarząb, B., Leenhardt, L., Musholt, T. J., Newbold, K., Nixon, I. J., Smit, J., Sobrinho-Simões, M., Sosa, J. A., Tuttle, R. M., Verburg, F. A., Wartofsky, L., & Führer, D.
- Venue
- Thyroid
- Publisher
- SAGE Publications
- Published
- 2019-01
- Volume
- 29
- Issue
- 1
- Pages
- 7-26
- ISSN
- 1050-7256 (ISSN-L)
- 1557-9077
- OpenAlex
- W2903130587
- Cited by
- 181
- References
- 120
- FWCI
- 12.79
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: European Perspective on 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: Proceedings of an Interactive International Symposium. https://app.cochat.ai/papers/10.1089/thy.2017.0129
- The paper
- Luster, M., Aktolun, C., Amendoeira, I., Barczyński, M., Bible, K. C., Duntas, L. H., Elisei, R., Handkiewicz-Junak, D., Hoffmann, M., Jarząb, B., Leenhardt, L., Musholt, T. J., Newbold, K., Nixon, I. J., Smit, J., Sobrinho-Simões, M., Sosa, J. A., Tuttle, R. M., Verburg, F. A., . . . Führer, D. (2019). European Perspective on 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: Proceedings of an Interactive International Symposium. Thyroid. https://doi.org/10.1089/thy.2017.0129
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.